Association between genetic polymorphism and adverse events or effectiveness of S-1-based chemotherapy in patients with gastrointestinal cancer

Association between genetic polymorphism and adverse events or effectiveness of S-1-based chemotherapy in patients with gastrointestinal cancer - TCO-TYMS2009

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000001892

Enrollment

100

Registered

2009-04-16

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastrointestinal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who either completed, currently recieving, or are going to receive S-1-based chemotherapy at Outpatient Oncology Unit, Kyoto University Hospital 2. Patients who have histologically confirmed, unresectable advanced or recurrent gastric, pancreatic, biliary tract or colorectal cancer 3. Patients who provided written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with at least 6 months S-1 free interval if they were re-treated by S-1-based chemotherapy (e.g. recurrence after adjuvant chemotherapy) 2. Patients who were judged ineligible by investigator

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events	—

Countries

Japan

Contacts

Public ContactTakafumi Nishimura

Kyoto University Hospital Outpatient Oncology Unit

nisimura@kuhp.kyoto-u.ac.jp

Outcome results